News Release
First Tin advances strategic tin projects in Australia and Germany to fill supply deficit
First Tin PLC
First Tin PLC CEO Bill Scotting joins Proactive's Stephen Gunnion with details of the two tin mining projects the company is developing in Australia and Germany. Scotting said the Taronga project, near Brisbane, will operate as an open pit mine and is expected to produce approximately 3,500 tonnes of tin concentrate annually. The German project, Tellerhäuser is being developed as an underground mine and will target multiple metals, including tin, indium, copper, and zinc. Both projects are situated in historic tin mining districts, with the German site dating back centuries. Scotting said technological advancements in mining and processing have enabled more efficient extraction and processing of tin. Market dynamics, such as increased tin pricing, have also improved the economic viability of these projects. Additionally, he noted that First Tin implements high environmental standards in its operations, including the use of solar power in Australia and adherence to strict environmental regulations in both countries. Scotting highlighted the growing global demand for tin, driven by its critical role in electronic manufacturing and the energy transition, including solar energy and electric vehicles. He noted a structural change in the market, with increasing tin usage in various high-tech applications. He also pointed out the strategic advantage of their mines' locations in OECD countries, which ensures a more stable and secure supply chain compared to tin sources in emerging economies. Contact Details Proactive UK Proactive UK +44 20 7989 0813 UKEditorial@proactiveinvestors.com
May 09, 2024 07:41 AM Eastern Daylight Time
Video
News Release
Eden Research reports strong growth and new product introductions in 2023
Eden Research PLC
Eden Research PLC CEO Sean Smith tells Proactive's Stephen Gunnion the company achieved significant advancements and a robust performance in 2023. Revenue for the year to 31 December 2023 increased by 78% to £3.2 million, surpassing market expectations. This growth was attributed to strong sales across various product lines. A noteworthy development was a successful fundraising event that raised £9.9 million, enhancing the firm's cash position and enabling further product development. In partnership with Corteva Agriscience, Eden introduced Ecovelex, a new seed treatment product designed to repel birds from maize, marking a new category for the company. This product received temporary approval in Italy, facilitating its use in the 2024 growing season. Additionally, Eden expanded its product range to include an insecticide targeting pests like mites and aphids, which has undergone extensive field testing with over 140 trials worldwide. Regulatory approvals for Mevalone were a significant focus, with expansions in the US including crucial approval in California, important for the grapevine fungicide market. Looking forward, Smith said the company is optimistic about 2024, despite potential challenges from climate conditions and regulatory dependencies. Key future developments include ongoing product label expansions and regulatory authorisations, particularly in Europe. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
May 09, 2024 07:39 AM Eastern Daylight Time
Video
News Release
Genflow Biosciences advances three major programs in fight against ageing diseases
Genflow Biosciences PLC
Genflow Biosciences PLC CE Dr Eric Leire tells Proactive's Stephen Gunnion the company had a successful year in 2023, allowing it to expand its research and development pipeline. Leire highlighted three main programs during an interview. The first focuses on MASH (Metabolic Dysfunction-Associated Steatohepatitis), soon progressing to clinical trials, indicating a strong move towards addressing liver diseases. The second program deals with Werner Syndrome, a progeria-related condition, where Genflow is innovating with synthetic organoids to mimic human organ function for better clinical trial predictions. The third program targets sarcopenia in collaboration with Revatis SA, aiming to combat muscle loss associated with ageing. The company has also engaged with regulatory agencies in Europe and the US, receiving positive feedback on its approach, particularly with its MASH program. It is awaiting further feedback from the FDA to decide the trial's location. In addition to a recent £715,000 fundraise, Genflow's financial strategy relies heavily on grants, with recent significant funding from the Wallonia Region in Belgium, which Leire believes positions it well to continue its work without heavy reliance on venture capital. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
May 09, 2024 07:37 AM Eastern Daylight Time
Video
News Release
Fah Mai Holdings' Jacob Carter provides expert insights on whisky investment
Fah Mai Holdings Group Inc
Fah Mai Holdings Group Inc (OTC:FMHG) UK head and manager of @whiskybullauctions Jacob Carter provides detailed advice for investors in the secondary whisky bottle market in an interview with Proactive's Stephen Gunnion. Carter emphasised the importance of conducting thorough research and developing a personal investment strategy, highlighting rarity and age as key factors in choosing investment bottles. He mentioned significant past investment successes, such as a 1964 Black Bowmore Aston Martin DB5 bottle bought for less than £100 and now valued at about £50,000. Carter advised using resources like Rare Whisky 101 to access data on highly traded bottles and stressed the necessity of understanding market dynamics, which can be influenced by distillery release schedules and other seasonal factors. He also discussed the critical aspects of storage and insurance for investment bottles, suggesting that collectors work with auction houses that provide these services. Authenticity verification, according to Carter, can involve checking cask and bottle numbers or consulting with distilleries directly. Contact Details Proactive UK +44 20 7989 0813 UKEditorial@proactiveinvestors.com
May 09, 2024 07:08 AM Eastern Daylight Time
Video
News Release
Seeing Machines advances with strategic expansions and strong quarterly performance
Seeing Machines Ltd
Seeing Machines Ltd CEO Paul McGlone joins Proactive's Stephen Gunnion with an update on the company's progress and key developments. McGlone highlighted the expansion with an existing US customer and a tier 1 supplier, driven by increasing regulatory requirements in Europe, which signifies a significant development for the company. This expansion includes new technology integrations and a stronger foothold in the European market, alongside additional volume in China. Further, McGlone discussed the company's recent performance following their third-quarter results, noting a return to normal production levels and the launch of a new major vehicle program. This contributed to Seeing Machines producing over 300,000 vehicles in the quarter, supporting a year-on-year growth rate of 100%. This performance reassured investors of the company's growth trajectory. Additionally, McGlone outlined the launch of their biggest ever production award with a significant European OEM, which includes a comprehensive interior sensing capability for driver and occupant monitoring. This project is seen as a major technical achievement and is expected to notably increase growth rates. McGlone also touched on the aftermarket segment, particularly their Guardian Connections system for trucks and buses, which showed consistent growth and is set to expand further with the rollout of their third-generation product. Lastly, McGlone reaffirmed the company's financial targets for 2024 and their aim to achieve cash break-even in 2025, indicating strong momentum across various business areas, including automotive, aviation, and fleet services. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
May 09, 2024 07:06 AM Eastern Daylight Time
Video
News Release
Light Science Technologies CEO discusses record 2023 results and strategic growth
Light Science Technologies Holdings PLC
Light Science Technologies Holdings PLC (AIM:LST) reported a record year in 2023 with CEO Simon Deacon highlighting significant achievements in an interview with Proactive's Stephen Gunnion. The company implemented a strategic plan focused on growth and profitability, exceeding expectations in both areas. Notably, its Controlled Environment Agriculture (CEA) segment and Contract Electronics Manufacturing (CEM) contributed robustly to revenue increases. The company achieved a gross margin of 23.4% and overall revenue growth of 13.8% to £9.3 million. Deacon also discussed the impact of strategic acquisitions, including Tomtech, which enhanced its offerings in controlled environment agriculture, integrating systems for vertical farms, polytunnels, and glasshouses. Another notable acquisition was Injecta Fire Barrier, a key asset in the passive fire protection market, poised for growth due to regulatory changes spurred by the Fire Safety Act of 2021. Additionally, the CEO outlined the use of a £1.45 million fundraise to support product development, acquisitions, and extend its cash runway. Looking forward, Deacon detailed milestones for 2024, including a significant contract in the sports entertainment electronics segment and anticipated revenue growth in passive fire protection. Overall, Deacon remains optimistic about sustaining momentum and achieving further growth. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
May 09, 2024 07:03 AM Eastern Daylight Time
Video
News Release
Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones
Immunic Inc
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt takes Proactive's Stephen Gunnion through the company's first-quarter achievements and upcoming milestones for its clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. Vitt said the quarter was notable for Immunic's successful fundraising efforts, raising up to $240 million in a three-tranche private placement aimed at furthering its Multiple Sclerosis (MS) and gastrointestinal treatments. He also highlighted the importance of the recent allowance of a fourth US patent for vidofludimus calcium, enhancing its intellectual property portfolio around MS treatments and ensuring long-term commercial exclusivity. Vitt gave an update on the status of ongoing clinical trials, including the advanced Phase 2 CALLIPER trial for MS, with significant results expected in April next year. Moreover, he touched on Immunic's gastrointestinal disorder programs, particularly for celiac disease, with the IMU-856 program showing promising results in restoring gut wall functions. The interview also covered upcoming milestones, focusing on executing current clinical trials and preparing for future phases. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com
May 09, 2024 06:58 AM Eastern Daylight Time
Video
News Release
Sostravel.com strategy unveiled: interview with Edoardo Zarghetta
SosTravel.com
SosTravel.com (OTCQB:SOSAF, EURONEXT:SOS) investor relations head Edoardo Zarghetta outlines the company's operations and strategic directions in an interview with Proactive's Stephen Gunnion. Sostravel.com operates primarily as a digital travel technology company with two business units. One focuses on packaging holidays, primarily in destinations such as Sardinia, southern Italy, Kenya, Turkey, Egypt, and Cuba, managing hotels and resorts to create custom holiday packages. The second unit provides technology services, including a Lost Luggage Concierge and Dr Travel for telehealth needs, enhancing travellers' experiences by addressing common issues like lost luggage and health care in foreign locales. The company benefits from a commercial relationship with shareholder TraWell Co SpA (OTCQX:TRWAF), which markets Sostravel.com's services at airports, enhancing visibility and customer acquisition. This relationship allows the implementation of unique marketing strategies focused on leveraging travel needs to introduce value-added services, distinguishing Sostravel.com from competitors by creating a symbiotic ecosystem between holiday offers and service provision. The company reported a 29.6% increase in gross booking value as of March and projects significant growth in revenues and EBITDA for 2024, with updates expected in August to confirm these forecasts. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com
May 09, 2024 06:56 AM Eastern Daylight Time
Video
News Release
Hostelworld CEO discusses strategic growth and market share increase
Hostelworld Group PLC
Hostelworld Group PLC (LSE:HSW, OTC:HSWLF) CEO Gary Morrison highlights significant advancements in the company's strategy and operational results in an interview with Proactive's Stephen Gunnion. The company, a key player in online hostel bookings, introduced social features in its app about two and a half years ago, aiming to enhance user interaction by connecting travellers based on their destination and stay dates. These features have been pivotal in increasing app downloads and subsequently, app-based bookings, which have grown 49% year-over-year, compared to a 27% increase in web bookings. Hostelworld's innovative social strategy, designed to cater primarily to solo travellers aged 18 to 35, has significantly boosted its market share. This strategy, coupled with an effective marketing approach, has led to a 34% increase in revenue and a 37% increase in net bookings year-over-year. Morrison also noted a geographical shift in the company's market, with substantial growth in Asia and continued strong performance expected in various global markets. Furthermore, he discussed the company's financial health, mentioning efficient cash conversion from EBITDA and strategic financial decisions, including a share repurchase program to offset dilution from previous share issuances. Looking forward, Hostelworld anticipates continued revenue and bookings growth, aligning with its strategic projections established in November 2021. Contact Details Proactive UK Proactive UK +44 20 7989 0813 UKEditorial@proactiveinvestors.com
May 09, 2024 06:52 AM Eastern Daylight Time
Video
